Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2022: Technologies Driving Biological Investigations

Extracellular Vesicles 2022: Technologies Driving Biological Investigations Agenda



Co-Located Conference Agendas

Extracellular Vesicles 2022: Technologies Driving Biological Investigations | 

Print Agenda

Monday, 12 December 2022

08:00

Please Refer to the Plenary Session Agenda for Details of Programming on Monday, December 12, 2022

Tuesday, 13 December 2022

08:00

Morning Coffee, Tea, Pastries and Networking in the Exhibit Hall


Session Title: A Deep Dive into Biological Investigations on Extracellular Vesicles (EVs)

09:00

Mei HeConference Chair

Welcome and Introduction and Overview of EV Field by Conference Co-Chairperson
Mei He, Assistant Professor, University of Florida, United States of America

09:15

Michael GranerConference Chair

Welcome and Introduction by Conference Chairperson and an Overview of the Field of EVs
Michael Graner, Professor, Dept of Neurosurgery, University of Colorado Anschutz School of Medicine, United States of America

09:30

Advancing Cancer Liquid Biopsy with Microfluidics and Nanoengineering
Yong Zeng, Associate Professor, University of Florida, United States of America

A primary focus of my research is on the development of innovative microfluidics and nanobiosensing technologies and molecular biomarkers for cancer diagnosis and treatment. Herein, we will discuss some of the nanoengineered microfluidic systems for efficient immunoisolation of circulating extracellular vesicles (EVs) and ultrasensitive profiling of EV biomarkers, including proteins and miRNAs.  Adaptation of our new technologies to clinical studies of circulating EVs for non-invasive liquid biopsy of cancer will be discussed.

10:00

Dominique PV de KleijnKeynote Presentation

Plasma Extracellular Vesicles For Cardiovascular Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. We use plasma extracellular vesicle (EV) protein content of vesicles from plasma sub-fractions on plasma of stroke and peripheral artery disease(PAD) patients, patients after carotid atherectomy (CEA) and patients suspected for chronic coronary syndrome (CCS). Using 25 ul of plasma, we developed an automated 96-well based protocol using sequential precipitation. Using samples of the AtheroExpress, the largest ongoing CEA biobank we try to early detect the risk of a second Major Adverse Cardiovascular Event (MACE: myocardial infarction, stroke or cardiovascular death) in PAD and CEA patients. Identification of such high risk patients is very important for possible (expensive) add-on pharmaceutical therapy or the decision to operate or not. Sequential precipitation for EV isolation is also used for the diagnosis of CCS.

10:30

Placental Cell-Specific Extracellular Vesicle (EV) Changes Throughout Gestation Quantitated by Nanoscale Flow Cytometry
Terry Morgan, Professor, Oregon Health and Science University, United States of America

Placental alkaline phosphatase (PLAP) positive EVs increase with gestational age and may be relatively increased early in pregnancy in women who develop severe pregnancy complications. Importantly, PLAP alone is not specific for placental EVs and multiplex antibody labeling is required to measure cell-specific events in plasma.  We employ nanoscale high resolution flow cytometry to reliably image, count, and isolate cell- and size-specific EVs in banked plasma.  This is the first study to demonstrate that most of the PLAP+ EV events in pregnant plasma arise from EVTs, not floating villi.

11:00

Mid-Morning Coffee, Tea and Networking in the Exhibit Hall

11:30

Kendall Van Keuren-JensenKeynote Presentation

exRNA Analysis In Biofluids to Differentiate Diseases and Injuries of the Nervous System
Kendall Van Keuren-Jensen, Professor and Deputy Director, Translational Genomics Research Institute, United States of America

Our laboratory characterizes the exRNA cell-free and EV cargo in biofluids for the information they can provide about changes associated with disease, injury processes and progression.

12:00

Regulation of Extracellular Vesicle Biogenesis In Tissue Repair
Brian Eliceiri, Professor, UC San Diego, United States of America

Extracellular vesicles (EVs) are released by defined intracellular trafficking machinery that can mediate paracrine signaling that affects immune responses and tissue repair.  Here, specific examples of how specific pathways and genetic models affect EV payloads, and how these payloads can be used to design custom engineered therapeutics.

12:30

Networking Lunch in the Exhibit Hall -- Visit Exhibitors and View Posters


Session Title: Technologies Driving the Extracellular Vesicles (EVs) Field

13:30

SpectradyneTrends in EV Characterization Technologies
Jean-Luc Fraikin, CEO, Spectradyne

Methods for characterizing EVs are evolving, and new technologies are being developed that deliver size, concentration, and fluorescent phenotyping, each to a varying degree of success.  Learn about how some of these new and cutting-edge technologies work, their strengths and weaknesses, and where we at Spectradyne see the technology landscape moving next.

14:00

Particle Metrix GmbH and CEO, Particle Metrix Inc., USABiomarker Co-localization Measurements (C-NTA) Using the New Particle Metrix ZetaView x30 Family
Sven Rudolf Kreutel, Chief Executive Officer, Particle Metrix GmbH and CEO, Particle Metrix Inc., USA

During the last decades, Nanoparticle Tracking Analysis (NTA) has emerged as a vital and fast characterization technology for biological nanoparticles like Extracellular Vesicles, Exosomes and Viruses. While classic NTA scatter operation feeds back particle size and total concentration, the fluorescence detection capability enables the user to gain specific biochemical information. Determination of biomarker co-localization however, is a challenging task for any analytical instrument. A new laser generation ensuring perfect overlap of the illumination volumes of individual channels paired with very fast switching times between fluorescence channels lay the foundation of co-localization nanoparticle tracking analysis (C-NTA) introduced recently by Particle Metrix. For the first time, we report results of co-localization measurements of reference material as well as real biological samples based on NTA technology on the new ZetaView® PMX-230 TWIN.

14:30

NanoFCMNanoflow Cytometry: Sensitive Sizing and Phenotyping of Single EVs
Clayton Deighan, North American Sales and Applications Manager, NanoFCM

This presentation will review the principles and practice of nano flow cytometry. Covering the operational and experimental parameters important to resolving and counting single EVs. The latest updates on the technical capabilities of nano flow will be provided and multiple published examples of the data will be presented.

15:00

Mid-Afternoon Coffee and Tea Break and Networking

15:30

IZON SciencePaving the Way to Automation and Standardization for Scalable Isolation of EVs
Anthony McNeil, Application Scientist, IZON Science

As the potential for EV-based diagnostics and therapeutics continues to grow, so too does the need for scalable isolation and precise characterization. In this presentation, I will present how technologies and services offered by Izon Science fill this gap. I will introduce Izon’s newly released Gen 2 qEV SEC isolation product line as well as our recent work on scaling up EV isolation and purification using larger sized qEV columns with automated flow systems. Finally, you will be taken through an overview of Izon platforms and offerings, to gain a clear understanding of how Izon technologies can fit into a larger workflow.

16:00

The Making of an Extracellular Vesicle Core
Paolo Neviani, Director - ExtraCellular Vesicle Core, Children’s Hospital Los Angeles, United States of America

The Children’s Hospital Los Angeles Extracellular Vesicle Core was founded in 2018, as the first core of this kind in the country, with the mission of providing the research community with expertise, optimized tools and up to date technologies dedicated to the field of EVs. The core provides isolation, characterization, and analysis of extracellular vesicles in an effort to facilitate EV research by adhering to the ever-evolving guidelines for standardization developed by the International Society of Extracellular Vesicles.

16:30

David JunckerKeynote Presentation

EV-ID: Highly Multiplexed Affinity Proteomics of Single Extracellular Vesicles Using Interference and Label-based Imaging
David Juncker, Professor and Chair, McGill University, Canada

17:00

Randy CarneyKeynote Presentation

Single Particle Analyses Toolbox: The Key to Unlocking the Heterogeneity of Extracellular Vesicles
Randy Carney, Assistant Professor, University of California-Davis, United States of America

The heterogeneity in composition and structure of individual EVs strongly contributes to their varied functions with respect to therapeutics. Yet it remains a challenge to examine structure-function at the resolution of single vesicles. In this talk, I will introduce a suite of high throughput commercial and custom tools that probe the structure and composition of single EVs, with a focus on spectroscopic techniques. I will examine best practices and key advantages of each technique, and provide an outlook of what is needed still to advance their study.

17:30

Steve SoperKeynote Presentation

Title to be Confirmed.
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

18:00

Close of Conference Day

Wednesday, 14 December 2022

08:00

Morning Coffee, Tea and Networking in the Exhibit Hall


Session Title: Emerging Areas in the Extracellular Vesicles (EVs) Space Including EV-based Therapeutics Development

09:00

Danilo TagleKeynote Presentation

Developing Technologies for Single Vesicle Isolation and for Regenerative Medicine
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Extracellular vesicles (EVs) are lipid membranous vesicles released from almost all cell types, and they provide a tremendous opportunity as sources of novel biomarkers from liquid biopsies, as well as agents for tissue repair and wound healing in regenerative medicine. EVs carry complex molecular cargoes, such as proteins, RNAs [e.g., mRNA and noncoding RNAs (microRNA, transfer RNA, circular RNA and long noncoding RNA)], and DNA fragments; these cargoes are delivered to recipient cells and serve as a cell-to-cell communication system. The molecular contents of EVs largely reflect the cell of origin and thus show cell-type specificity. Exosomes are endogenous nanoparticles that constitute a fraction of extracellular vesicles that are secreted by all cell types into the extracellular environment, and play an important role in intercellular signaling.  Exosomes are being utilized in a variety of biomedical applications, including targeted drug delivery, gene therapy, diagnosis, and tissue regeneration. Despite significant efforts made in this relatively new field of research, progress has been held back by challenges such as inefficient separation methods, difficulties in characterization, and lack of specific biomarkers. This presentation will elaborate on the NIH support for exosome isolation, as well as its potential use in regenerative medicine.

09:30

ILIAS Biologics Inc.Exosome Engineering for Active Targeting and Intracellular Delivery of Therapeutic Proteins: Realization from Concept
Chulhee Choi, CEO, ILIAS Biologics Inc.

As extracellular vesicles that play an active role in intercellular communication by transferring cellular materials to recipient cells, exosome offer great potential as a natural therapeutic drug delivery vehicle. Currently, both academia and industry try to develop exosome platform-based therapeutics for disease management, some of which are already in clinical trials. An opto-genetically engineered exosome system (EXPLOR®) that we previously developed was implemented for loading therapeutic cargo into exosomes which can deliver therapeutic cargos into target cells in free form. We are studying the clinical potential of ‘Exo-target®’, therapeutic exosomes with EXPLOR technology, in multiple disease areas including inflammatory diseases. NF-kB has been well accepted as master regulator for inflammation. The introduction of I-kB into target cells can inhibit inflammatory responses by restraining nuclear translocation of NF-kB. Therefore, we have developed Exo-target loaded with dominant active form of I-kB (Exo-srI-kB). We found that Exo-srI-kB treatment attenuates both local and systemic inflammation and animal mortality associated inflammatory disease including sepsis, ischemic reperfusion induced acute kidney injury and preterm birth in our preclinical studies. Especially, maternally injected Exo-srI-kB could cross-over placenta barrier to deliver therapeutic cargos to fetal side, which resulted in prolonged pregnancy by more than 24 hours and additional advantages. Altogether, these results suggest therapeutic value of Exo-target for various disease by delivering API intracellularly to the target cells.

10:00

Microfluidic Technologies for the Isolation and Characterization of Extracellular Vesicles For Lung Cancer Theranostics
Sunitha Nagrath, Professor of Chemical Engineering and Biomedical Engineering, University of Michigan-Ann Arbor, United States of America

The extracellular vesicle (EV) has emerged as one of the diagnostic means of cancer through liquid biopsy. So far, ultracentrifugation has been accepted as gold standard for EV isolation in spite of its lengthy processing time and low recovery rate. Owing to the recent technological advances in microfluidics, several microfluidic devices for EV isolation have been developed and showed promising with better recovery rate and processing time. Here we present microfluidic based approaches to isolate and profile tumor derived EVs. To demonstrate the harvesting of EVs from specific cells for therapeutic use we have developed a microfluidic based strategy to harvest EVs from Natural Killer (NK) cells in blood circulation. In combination we have developed theranostics application of EVs in lung cancer.

10:30

Coffee Break and Networking in the Exhibit Hall

11:00

Nanotransfection-Driven Extracellular Vesicles for Therapeutic Applications
Daniel Gallego-Perez, Associate Professor, The Ohio State University, United States of America

11:30

Probing Life in Bubbles – Nanoplasmonic Quantification of Pathogen-derived Extracellular Vesicles in Blood
Tony Hu, Professor and Presidential Chair, Tulane University School of Medicine, United States of America

Extracellular vesicles (EVs) are small membrane-bound vesicles secreted by all cells, circulate at high levels, and convey nucleic acids, peptide/proteins, lipids. EVs secreted by microbial pathogens or infected or malignant cells represent an excellent source of biomarkers, but technical challenges have prevented development of EV-based assays. With the advanced technologies, we have identified and validated new biomarkers for rapid pathogen differentiation (e.g. SARS-CoV-2 and mycobacterial), early disease diagnosis (including cancer), and/or real-time evaluation of disease response. Our multidisciplinary expertise enables us to employ the characteristic properties of engineered nanodevices to improve the capture and detection of circulating biomarkers.

12:00

Engineered Extracellular Vesicles for Therapeutic Applications
Natalia Higuita-Castro, Assistant Professor, The Ohio State University, United States of America

12:30

Networking Lunch in the Exhibit Hall -- Visit Exhibitors and View Posters

13:30

Jennifer JonesKeynote Presentation

Title to be Confirmed.
Jennifer Jones, NIH Stadtman Investigator, Head of Transnational Nanobiology, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, United States of America

14:00

Title to be Confirmed.
John Tigges, Flow Cytometry Science Center Director, Beth Israel Deaconess Medical Center, United States of America

14:30

Title to be Confirmed.
Yazhen Zhu, Assistant Professor, David Geffen School of Medicine at UCLA, United States of America


Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonExtracellular Vesicles 2022: Technologies Driving Biological InvestigationsExtracellular Vesicles 2022: Technologies Driving Biological Investigations in Long Beach, CaliforniaLong Beach, CaliforniaSELECTBIOenquiries@selectbiosciences.com